The company's last update was positive, so why are Polynovo (ASX:PNV) shares still among the most shorted on the ASX?

Short sellers are targeting Polynovo shares…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Polynovo shares up 2.33% yesterday, but down close to 14% for 2022
  • Investors are heavily targeting Polynovo shares with a short interest of 8.89%
  • The company's inconsistent performance is weighing down investor sentiment

The Polynovo Ltd (ASX: PNV) share price has continued to decline despite the company reporting positive numbers in mid-January.

While the medical device company's shares rose 2.33% to $1.315 yesterday, it hasn't been so great in 2022. In fact, for the past 6 weeks (year to date), Polynovo shares have tumbled by almost 14%.

Below, we take a look at what is impacting the company's share price of late.

A small child carrying a brief case tries to reach an elevator button outside closed elevator doors.

Image source: Getty Images

Polynovo shares in top 10 open ASX short positions

The investor sentiment on the Polynovo share price has been negative due to the inconsistent performance of the business. This has ultimately attracted a large number of short sellers to the company's registry.

Short-selling is a common trading strategy that aims to profit from the fall in the price of a security. The goal is for an investor to first borrow and sell the shares, and then buy them back at a lower price for a profit.

Last week, the Australian Securities & Investments Commission (ASIC) released its short position report revealing the level of short interest within companies.

As such, Polynovo remained in the top 10 list with 8.89% of its shares being heavily shorted by investors.

In comparison, the government body had a short interest of 3.65% in Polynovo last year on 4 February.

Given the large increase in short positions being taken up, it appears investors believe the company's performance will be underwhelming.

Polynovo is scheduled to release its FY22 half-year results within the next two weeks.

Polynovo share price snapshot

Over the past 12 months, the Polynovo share price has continued its downward trend to post a 50% loss.

In comparison, the S&P/ASX 200 Healthcare (ASX: XHJ) sector has lost around 5% in the same time frame.

It's worth noting that Polynovo shares hit a multi-year low of $1.185 late last month. This is a huge difference from when its shares were trading above the $4 mark in December 2020.

Polynovo presides a market capitalisation of about $870.12 million and has approximately 661.69 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Why this ASX healthcare stock is a top rebound candidate with big upside 

This could be a perfect buy-low candidate.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

2 ASX healthcare stocks tipped to return 34% to 63%

These companies could be poised for much bigger things.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
ASX Share Market News

Are Pro Medicus shares now too cheap to ignore?

The discount looks tempting, but slowing growth could expose valuation risks.

Read more »

Two ASX share investors sharing a secret.
Healthcare Shares

Cochlear shares are quietly rebounding: Is a bigger rally coming?

After a 58% plunge, Cochlear doesn’t need perfection to surprise investors.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech is tipped to more than double in value

Encouraging trial results have the analysts excited.

Read more »

person climbing mountain
Healthcare Shares

CSL share price forecast: How high could it climb in the next year?

CSL shares could roar back, but investors need more than hope.

Read more »

Two CEOs shaking hands on a deal.
Healthcare Shares

Integral Diagnostics: FY26 results and new CFO appointment

Integral Diagnostics delivered double-digit profit growth and appointed a new CFO.

Read more »

Woman looking at stock market numbers.
Healthcare Shares

CSL shares are rising: 3 things investors need to watch

CSL’s FY26 result could reveal whether the turnaround has finally begun.

Read more »